Barbiturate and anticonvulsant treatment in relation to osteomalacia with haemodialysis and renal transplantation.
Among 39 patients treated by regular haemodialysis for four years or more pathological fractures and histological evidence of osteomalacia were significantly more common in those taking barbiturates. Out of 58 transplant recipients surveyed after one year, seven had osteomalacia; four of these had been taking phenobarbitone and phenytoin and one had taken barbiturates alone. Sedatives and other drugs such as phenobarbitone and phenytoin that induce hepatic microsomal enzymes should probably be avoided when possible in patients with chronic renal failure and after transplantation.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001463:Barbiturates / Q000009:adverse effects*; D001842:Bone and Bones / Q000473:pathology; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000139:chemically induced*; D010634:Phenobarbital / Q000009:adverse effects; D010672:Phenytoin / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects*
D001463:Barbiturates; D010672:Phenytoin; D003404:Creatinine; D000469:Alkaline Phosphatase; D010634:Phenobarbital